Potential use of immunoconjugates for AIDS therapy.
More than a dozen of hybrid proteins possessing reactivity with human immunodeficiency virus-type 1-(HIV-1) infected cells and cytotoxicity have been produced and studied by several groups. These proteins are prepared either by chemical cross-linking of a toxin and a carrier molecule or by expressing fused genes of the two moieties. These cytotoxic agents have been investigated to eliminate HIV-1-infected cells in vitro. The ID50 of these agents range from pM to nM. This article compares the results of the various approaches and discusses the limits and potential of immunoconjugates for AIDS therapy.
Kim
Y W
YW
Tanox Biosystems, Inc., Houston, TX 77025.
Chang
T W
TW
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*
D000922:Immunotoxins